GLB1

The GLB1 gene encodes β-galactosidase, a lysosomal enzyme responsible for breaking down complex sugars like gangliosides and glycoproteins, particularly in neural and connective tissues. 

Mutations in GLB1 lead to two distinct autosomal recessive disorders—GM1 gangliosidosis and Morquio B syndrome—each associated with specific patterns of neurologic or skeletal involvement.

What is GLB1 (Galactosidase Beta 1)?

The GLB1 gene, located on chromosome 3p22.3, encodes β-galactosidase, a lysosomal enzyme essential for breaking down some complex sugars. Specifically, β-galactosidase degrades glycosphingolipids and glycoproteins, including ganglioside GM1 and keratan sulfate. 

These substrates are critical in neural tissues, cartilage, and the cornea. Through alternative splicing, GLB1 also produces an elastin-binding protein (EBP), which has a non-enzymatic role in elastic fiber formation in connective tissues.

When is GLB1 Enzyme Activity or Genetic Testing Relevant?

GLB1 testing may be relevant in the following clinical scenarios:

Suspected GM1 Gangliosidosis or Morquio B Syndrome (MPS IVB)

GLB1 testing is indicated in individuals showing clinical signs of either GM1 gangliosidosis or MPS IVB, which are autosomal recessive lysosomal storage disorders caused by β-galactosidase deficiency.

GM1 Gangliosidosis

GM1 gangliosidosis is a rare, inherited lysosomal storage disorder caused by mutations in the GLB1 gene. It leads to deficient activity of the enzyme β-galactosidase and toxic accumulation of GM1 ganglioside in the nervous system. 

The disease presents as a spectrum—from severe infantile-onset neurodegeneration to milder adult forms—with no FDA-approved therapies. However, gene therapy and other experimental treatments are under active investigation.

GM1 Gangliosidosis presents with varying severity:

• Type I (infantile): Onset before 1 year; rapid developmental regression, cherry-red macula, seizures, skeletal abnormalities, organomegaly, and early death.
• Type II (late-infantile/juvenile): Onset between ages 1–10; slower regression, skeletal changes, and cardiac involvement. Death usually occurs in late childhood to early adulthood.
• Type III (adult/chronic): Onset in adolescence or adulthood with dystonia, parkinsonism, skeletal deformities, and mild cognitive decline.

Morquio B Syndrome (Mucopolysaccharidosis Type IVB)

Mucopolysaccharidosis type IVB (Morquio syndrome type B) is a rare autosomal recessive lysosomal storage disorder caused by deficiency of the enzyme β-galactosidase due to mutations in the GLB1 gene. 

Clinically indistinguishable from MPS IVA, it leads to progressive skeletal abnormalities, joint hypermobility, corneal clouding, and respiratory complications while sparing cognitive development.

MPS IVB (Morquio B Syndrome) is primarily skeletal, presenting with the following symptoms:

• Characterized by short stature, joint laxity, kyphoscoliosis, odontoid hypoplasia, and possible corneal clouding.
• Neurologic function is typically preserved, and life expectancy is often normal.

Biochemical Confirmation

Enzyme assays in leukocytes or fibroblasts can measure β-galactosidase activity. Significantly reduced levels confirm diagnosis:

• Type I GM1: negligible activity
• Type II: ~1–10%
• Type III: ~5–12%
• MPS IVB: ~2–12%

Family History or Carrier Screening

Genetic testing is also appropriate for relatives of affected individuals, especially when planning pregnancies. Carrier testing can identify individuals at risk of passing on GLB1-related disorders.

Differential Diagnosis

GLB1 testing helps distinguish GM1 gangliosidosis or MPS IVB from other lysosomal storage disorders that may have overlapping symptoms.

What Do Low Levels of GLB1 Enzyme Activity Mean?

Markedly reduced or absent β-galactosidase activity is diagnostic for either GM1 gangliosidosis or MPS IVB. 

Enzyme activity levels often correlate with disease severity, with lower activity linked to more severe phenotypes. However, there is some variability, and testing should always be interpreted in the clinical context.

Beta-Galactosidase Enzyme Activity Testing

Beta-galactosidase enzyme activity is measured using a blood or skin sample. The test is performed on peripheral blood leukocytes or cultured skin fibroblasts in a laboratory. 

It uses specific substrates to determine the amount of enzyme activity present, helping to confirm a diagnosis of GLB1-related disorders.

GLB1 Genetic Testing: Test Procedure and Interpretation

Testing for GLB1 is performed as a genetic test to look for mutations in the gene that would alter functional protein availability. The following section outlines the testing procedures and interpretation.

Testing Procedure and Preparation

Genetic testing involves blood, saliva, or cheek swab samples, although specialized laboratories may recommend different sample types. 

A cheek swab or saliva sample is easily obtained from the comfort of home, while blood samples typically require a blood draw.

Normal Reference Ranges

Normal reference ranges for GLB1 genetic testing are considered to be without mutations that can alter the activity of the GLB1 proteins.

What Do Specific GLB1 Mutations Mean?

Specific mutations may carry the following significance:

Confirming Diagnosis

Identifying two pathogenic mutations in GLB1 confirms a diagnosis of GM1 gangliosidosis or MPS IVB.

Inheritance Pattern

Both conditions follow an autosomal recessive inheritance pattern. 

Parents of affected individuals are carriers, and each sibling has a 25% risk of being affected, a 50% chance of being a carrier, and a 25% chance of being unaffected.

Genotype-Phenotype Correlation

Mutations that severely impair the enzyme's active site tend to cause Type I (infantile) GM1 gangliosidosis.

Milder mutations affecting protein stability or trafficking are associated with later-onset GM1 or MPS IVB.

The p.Trp273Leu mutation is frequently linked to MPS IVB, while variants like p.Arg59His and p.Asp448Val are associated with GM1.

Some mutations affect both isoforms of the GLB1 protein, leading to mixed neurological and skeletal features.

What Does the Absence of Pathogenic GLB1 Mutations (with Low Enzyme Activity) Mean?

In rare cases, using standard sequencing methods, enzyme activity may be low without detectable mutations. Possible explanations include:

• Deep intronic variants not captured by typical tests
• Structural genomic variants (e.g., large deletions): In such cases, extended testing, including whole genome sequencing or copy number analysis, may be warranted.

Order Genetic Testing

Click here to compare genetic test panels and order genetic testing for health-related SNPs.